The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the growing appetite of private equity firms for the European healthcare sector, a consortium led by CVC Capital Partners and GBL has launched a formal bid for Recordati. The offer is valued at 10.7 billion euros, approximately $12.5 billion, with the intent to take the Italian pharmaceutical firm private and delist it from Euronext Milan. According to reports, the acquisition is designed to support the company’s strategic expansion into the rare disease treatment market.
This bid arrives amid a wave of consolidation in the European pharma space, as firms compete for high-margin assets. Compared to previous sector deals, such as Sanofi's $2.9 billion acquisition of Provention Bio last year, the Recordati offer stands out as one of the largest recent buyouts in specialty pharmaceuticals. Per market data, the valuation reflects a premium consistent with private equity's desire to secure stable cash flows in defensive sectors.
Sign in to access this content
Sign InTraders are monitoring price levels in Milan to gauge alignment with the offer price, noting that Italy's Balance of Trade recorded a surplus of 4.709 billion euros as of May 18, 2026. Looking ahead, the success of the deal hinges on regulatory and shareholder approvals. Investors should watch for further disclosures regarding financing structures and potential counter-bids in the coming sessions.